Featured Entrepreneurs

Since 2010, MassChallenge has accelerated 2,344 startups that have raised more than $5 billion in funding, generated more than $2.7 billion in revenue, and created more than 126,000 total jobs. 

Our startups

Be inspired. Search our startups.


Prostate cancer is the most common malignancy diagnosed among men.Transrectal biopsy is a gold standard for detecting it. Patients undergoing this procedure are exposed to urinary tract infections leading even to sepsis. Treatment cost of prostate biopsy-related complications and insurance payouts is estimated at $1.7 bn in the USA and EU. DEBN delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start reducing risk significantly
DEBN is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate.

Connect with DEBN


2019 Finalist Switzerland

Sub industry

Medical Devices


MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.